Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.